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ABSTRACT 
Acute  Myocardial  Infarction  (AMI)  is  the  combined  result  of  environmental  factors  and  personal 
predispositions. Many factors play a role in AMI including anti-Phospholipid (aPL) antibodies, that 
may  act  in  the  induction  of  immunological  response  leading  to  the  development  of  AMI.  Anti-
Phosphatidylserine (PS) antibody is detected in various diseases like rheumatoid arthritis, systemic 
lupus erythematosus and anti-phospholipid antibody syndrome. The study of anti-PS antibody in AMI 
might shed light on etiologic mechanisms in the pathogenesis of acute coronary syndromes. This study 
was conducted to evaluate whether prevalence of anti-PS antibodies, in patients who had AMI and to 
analyze their relationship with traditional cardiovascular risk factors. The prevalence of anti-PS IgG 
and  IgM  in  a  well  characterized  group  of  patients  with  AMI  as  a  case  group  and  in  age  and  sex 
matched healthy subjects as control group. Sera from two groups were tested to evaluate the presence 
of IgG and IgM isotypes to anti-PS by ELISA method. The frequencies of positive test for anti-PS IgG 
were 26.70 and 8.90% among patients and controls respectively with significant difference (p = 0.003). 
The  anti-PS  IgM  frequencies  were  12.20  and  1.10%  in  patients  and  the  controls,  with  significant 
difference (p = 0.005). The findings of this study suggest that anti-PS antibodies seemed to play a role 
in AMI, independent risk factors for AMI, which  may represent a link between autoimmunity and 
atherosclerosis in patients with AMI. Further studies with bigger sample size including patients with 
AMI and healthy people are recommended to explore the exact role of anti-PS antibodies in AMI. 
 
Keywords: Anti-Phosphatidylserine  (PS)  Antibodies,  Acute  Myocardial  Infarction  (AMI),  Anti-
Phospholipid (aPL) Antibodies, Cardiovascular Ischemia  
1. INTRODUCTION 
Cardiovascular  Disease  (CVD)  is  one  of  the 
important causes of deaths despite developments in the 
medical interventions. Among these, the ischemic heart 
diseases,  Acute  Myocardial  Infarction  (AMI)  in 
particular,  is  one  of  the  most  alarming  values 
(Upaganlawar et al., 2011). 
Myocardial Infarction (MI) is the collective result 
of environmental factors, personal predispositions and 
genetics  (Shojaie  et  al.,  2013).  Factors  such  as  low 
serum  adiponectin  (Shojaie  et  al.,  2009a)  and  low Abdolreza Sotoodeh Jahromi et al. / American Journal of Immunology 9 (4): 96-100, 2013 
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annexin V levels (Shojaie et al., 2009b) and infectious 
diseases  such  as  Mycoplasma  pneumonia   
(Pourahmad  et  al.,  2009)  are  a  part  of  involving 
factors  in  AMI.  It  has  been  demonstrated  that  the 
immunopathological  such  as  anti-beta2  glycoprotein-I 
antibody (Shojaie and Jahromi, 2011) and Inflammatory 
processes (Jahromi et al., 2010a) have important roles in 
the initiation and development of AMI. 
Antiphospholipid  antibodies  (aPL)  in  addition  to 
habitual abortion and pregnancy loss (Jahromi et al., 
2010b)  are  associated  with  CVD  (Shojaie  and 
Jahromi, 2011; Jafarzadeh et al., 2011). However their 
pathogenic  mechanisms  are  still  matter  of 
investigation. 
Besides the Classical Lupus Anticoagulant (LAC) 
and  Anti-Cardiolipin  Antibodies  (ACA),  other  anti-
Phospholipid Antibodies (aPL) were shown to target 
anionic  phospholipids  and  other  plasma  proteins, 
including  phosphatidylethanolamine,  protein  C, 
protein S, ß2-Glycoprotein I (beta2-gpI) and annexin 
V (Tincani et al., 2010). 
The  results  of  some  studies  also  demonstrated  a 
realationship  between  anti-PL  antibody  and  IHD 
(Shojaie and Jahromi, 2011; Jafarzadeh et al., 2011; 
Hisham et al., 2007). It should be noted that genetic 
factors as well as other traditional risk factors such as 
smoking, hypercholesterolemia, diabetes mellitus and 
hypertension may contribute to IHD development and 
these  parameters  differ  among  various  population. 
Even though there are a few studies on the association 
of  some  autoantibodies  with  AMI,  more 
epidemiological  data  are  needed  to  confirm  their 
significance  as  independent  risk  factors  in  CVD. 
Furthermore,  the  data  on  the  correlation  of 
autoantibodies with traditional risk factors of AMI is 
scarce. Hence, this case control study was conducted to 
evaluate  the  serum  levels  of  Anti-Phosphatidylserine 
(PS) antibodies (IgG and IgM) in Iranian patients with 
AMI  and  also  to  explain  their  association  with  some 
traditional risk factors of this disease.  
2. MATERIALS AND METHODS 
2.1. Subjects 
 A  total  of  90  consecutive  patients  (aged  41-67 
years)  with  AMI  including  67  men  and  23  women 
who were admitted to Peymanieh Hospital of Jahrom 
(a southwest city of Iran), were enrolled to this case-
control study. 
AMI  was diagnosed by the presence of two of the 
following  criteria:  (i)  prolonged  chest  pain  compatible 
with  AMI,  (ii)  typical  ECG  changes,  (iii)  rising  of 
cardiac  enzymes  such  as  creatine  kinase  and  lactate 
dehydrogenase (Kushner et al., 2009).  
Exclusion  criteria  were  valvular  heart  disease, 
surgery, trauma during the prior month, cardiomyopathy, 
liver disease, renal failure, arthritis, malignant diseases, 
other  inflammatory  diseases  (such  as  rheumatoid 
arthritis  and  systemic  lupus  erythematosus)  and  oral 
anticoagulant therapy. In patients with AMI, the serum 
concentration  of  Anti-PS  antibodies  was  measured 
during 3-5 days after admission.  
An  age,  sex  and  other  CAD  risk  factors  such  as 
Hypertension  (HTN),  Diabetes  Mellitus  (DM)  and 
Hyper Lipidemia (HLP) matched group (n = 90) with 
similar  geographic  and  socioeconomic  backgrounds 
without  any  ischemic  heart  disease  were  used  as  a 
control  group.  All  control  subjects  were  basically 
healthy, with no acute or chronic illnesses and did not 
use  any  drugs.  The  healthy  control  group  was 
recruited from blood donors attending Jahrom Blood 
Transfusion Center.  
The study protocol was approved by research ethics 
committee  of  Jahrom  University  of  Medical  Sciences 
and  informed  consents  were  obtained  from  all 
participants  before  enrollment.  The  patient  or  his/her 
legal representative provided written informed consent. 
Historical,  demographic  and  clinical  data  were 
obtained  through  a  review  of  medical  records  and 
interviews  with  patients  and  their  families. The  risk 
factors for myocardial infarction were as following. 
(a)  age,  sex;  (b)  history  of  hypertension  (diagnosis 
confirmed when the systolic or diastolic pressures were 
>160 or  95  mm  Hg,  respectively,  or  when  the  patient 
was using antihypertensive medication) 12; (c) smoking, 
according  to  the  criteria  of  the  British  Council  for 
Medical  Research;  (d)  history  of  heart  disease  (atrial 
fibrillation or coronary heart disease, defined as previous 
myocardial  infarction,  angina,  or  revascularization 
procedure); (e) history of diabetes mellitus, according to 
the  medical  history  or  the  use  of  insulin  or  an  oral 
anti-diabetes drug; (f) hypercholesterolemia, based on 
total cholesterol >200 mg dL
-1, LDL-cholesterol >130 
mg dL
-1, or total cholesterol/HDL-cholesterol ratio >5 
(Donahue et al., 1988).  Abdolreza Sotoodeh Jahromi et al. / American Journal of Immunology 9 (4): 96-100, 2013 
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Blood  samples  (5  cc)  were  obtained  by  venipuncture 
from  the  patients  immediately  after  admission  before 
starting  any  IV  medications  by  skilled  personnel.  Blood 
samples were centrifuged and frozen within, at most, 2 h 
after collection and stored at -20°C until laboratory testing. 
Enzyme-immunoassay  kits  (Orgentic  Diagnostika 
from  Mainz,  Germany)  were  used  to  detect  IgG  or 
IgM  anti-PS  by  indirect  enzyme  linked 
immunosorbent assay (ELISA) method. The IgG and 
IgM  isotypes  results  were  assessed  in  IgG 
Phospholipid  (GPL)  and  IgM  phospholipid  (MPL) 
units, with one unit equal to 1  g mL
-1 of IgG or IgM. 
They  were  considered  positive  if  the  titer  was  >10 
GPL  units  and >10 MPL  units  for  both isotypes,  as 
recommended by the ELISA kits manufacturer. 
Statistical analyses were performed by SPSS (version 
17;  SPSS,  Inc.,  Chicago,  IL).  Data  were  expressed  as 
mean  ±  SD.  Continuous  variables  with  little-to-mild 
skewness were summarized as mean ± SD and compared 
using Student’s t-test. 
3. RESULTS 
The demographic and clinical characteristics of the 
study groups, as well as laboratory findings are shown 
in Table 1.  
In the patient group, 16 cases (18.80%) had Non-St 
Elevation  MI  (NSTEMI)  and  74  (82.20%)  had  ST 
Elevation MI (STEMI). 
There was no significant difference between the two 
groups regarding the following variables: age, sex, HTN, 
DM, LDL, HDL, total cholesterol and TG. 
We examined the association between positive anti-PS 
IgG and IgM tests and selected cardiovascular risk factors. 
There was a significant association between positive 
anti-PS IgG and IgM tests with Type hypertension. But 
there was not found any significant association between 
positive anti-PS IgG and IgM test with Type 1 DM, Type 
2 DM, age, sex, LDL, HDL, TG, total cholesterol and 
adjusted smoking. 
There was not found significant difference between 
positive anti-PS IgG tests in patients with STEMI and 
those with NSTEMI (73.30 Vs 25.90%), (p = 0.186) and 
also there was not found significant difference between 
positive anti-PS IgM tests in patients with STEMI and 
those with NSTEMI (74.10 Vs 26.70%), (p = 0.324). 
4. DISCUSSION 
The  results  of  the  present  study  showed  that  the 
prevalence  of  positive  anti-PS  IgG  and  also  IgM  in 
patients  with  AMI  were  significantly  higher  than  that 
observed  in  healthy  control  group.  These  associations 
were independent of traditional risk factors. It was found 
that the high prevalence of anti-PS antibodies in patients 
with  AMI  Vs  healthy  control  group  in  parallel  with 
previous studies (Jafarzadeh et al., 2011; Hisham et al., 
2007) consistent with current concepts on the immune 
pathogenesis  of  atherosclerosis.  However,  the  precise 
mechanisms of involvement of anti-PS antibodies in the 
pathogenesis of AMI remain to be determined. 
An association between CAD and AMI with Other aPLs 
have  been  reported  in  previous  studies  (Shojaie  and 
Jahromi, 2011; Jafarzadeh et al., 2011; Greco et al., 2010). 
 
Table 1. Demographic, clinical characteristics and laboratory finding for the case and the control groups 
Variables  Patients group  Control group  P-value 
Age (year)  9.63±62.66  10.63±6o.53  0.609 
Male (%) numbers  67 (74.40%)  68 (75.60%)  0.863 
High blood pressure (%) numbers  39 (43.33%)  28 (31.10%)  0.079 
Smoker (%) numbers  40 (44.40%)  32 (35.60%)  0.287 
IDDM * (%) numbers  24 (26.70%)  28 (31.10%)  0.622 
Total cholesterol * Mg/dL  40.30±176.13  43.20±168.80  0.104 
HDL-C * Mg/dL  9.11±44.20  10.29±42.83  0.328 
LDL-C * Mg/dL  36.32±118.05  30.64±98.22  0.093 
TG * Mg/dL  72.18±126.53  41.52±114.84  0.104 
FBS * Mg/dL  54.48±134.20  53.91±127.08  0.495 
Positive Anti-PS IgG (%) numbers  24(26.70%)  8 (8.90%)  0.003 
Positive Anti-PS IgM (%) numbers  11 (12.20%)  1 (1.10%)  0.005 
*IDDM = Insuline Dependent Diabetes Mellitus, NIDDM = Non-Insuline Dependent Diabetes Mellitus, HDL-C = High Density 
Lipoprotein-Cholesterol, LDL-C = Low Density Lipoprotein-Cholesterol, FBS = Fasting Blood Sugar, Anti-PS = Anti-Phatidylserine Abdolreza Sotoodeh Jahromi et al. / American Journal of Immunology 9 (4): 96-100, 2013 
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There was not found correlation between anti-PS IgG 
and  also  IgM  and  standard  cardiovascular  risk  factors 
such  as  smoking,  hypertension  and  diabetes,  as  seen 
about other apl antibodies in a previous study (Shojaie 
and Jahromi, 2011). 
In  this  study  there  was  a  significant  association 
between  anti-PS  IgG  with  HTN  in  the  case  and  the 
control groups. The same results were found about anti-
PS IgG in AMI in other studies (Hisham et al., 2007). 
These results suggest that anti-PS IgG are independent of 
these variables. 
As  there  were  not  significant  differences  between 
positive anti-PS antibodies test in patients with STEMI 
and those with NSTEMI, it can be concluded that anti-PS 
IgG and IgM do not participate in kind of AMI (STEMI 
vs NSTEMI). But, unfortunately, there were not found 
any data indicating association of anti-PS IgG and IgM 
with these parameters to compare the results. 
5. CONCLUSION 
These results show an association between AMI and 
high prevalence of positive tests for anti-PS IgG and 
IgM. The results of this study in parallel with the data 
from  other  studies  (Shojaie  and  Jahromi,  2011; 
Jafarzadeh et al., 2011; Greco et al., 2009; Urbanus et al., 
2009;  Hisham  et  al.,  2007)  support  the  potential 
important role of aPL antibodies in AMI. 
Further studies with larger sample size of patients and 
healthy subjects are recommended to explore the precise 
role of anti-PS IgG and IgM in AMI. 
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